Dimethyl Fumarate

EUEMA:by INN L04AX07(WHO) UK:POM(Prescription only)US:℞-onlyEU:Rx-only Dimethyl (2E)-but-2-enedioate 624-49-7Y 637568 7045 DB08908Y 553171Y FO2303MNI2 D03846 CHEBI:76004Y ChEMBL2107333 DTXSID4060787 Interactive image O=C(OC)\C=C\C(=O)OC InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+YKey:LDCRTTXIJACKKU-ONEGZZNKSA-NY Dimethyl fumarate(DMF) is the methylesteroffumaric acid.Dimethyl fumarate combined with three otherfumaric acidesters (FAEs) is solely licensed in Germany as an oral therapy forpsoriasis(brand nameFumaderm).Since 2013, it has been approved by the U.S.Food and Drug Administration(FDA) as a treatment option for adults with relapsingmultiple sclerosis(brand nameTecfidera).In 2017, an oral formulation of dimethyl fumarate (brand name Skilarence) was approved for medical use in the European Union as a treatment for moderate-to-severe plaque psoriasis.Dimethyl fumarate is thought to haveimmunomodulatoryproperties without causing significantimmunosuppression. Dimethyl fumarate has also been applied as abiocidein furniture or shoes to prevent growths ofmoldduring storage or transport in humid climates. However, due to cases of allergic reactions after skin contact, dimethyl fumarate-containing consumer products are no longer authorised to be manufactured (since 1998) or imported (since 2009) in theEuropean Union.Dimethyl fumarate is available as ageneric medication.